COVID-19 antiviral still effective against Omicron, real-world studies show
Nirmatrelvir–ritonavir halves the risk of death and hospitalisation in patients with mild COVID-19, studies show.
Nirmatrelvir–ritonavir halves the risk of death and hospitalisation in patients with mild COVID-19 at risk of severe disease — even during the Omicron variant era — two large studies confirm.
International researchers say the studies, with a combined 205,000 adults, are the first to assess the real-world effectiveness of the antiviral in non-hospitalised patients infected with the BA.2, BA.4 and BA.5 subvariants.
